Vaccine Concepts
Part of Public Health
Core concepts in vaccine science: antigens, adjuvants, schedules, efficacy, and how to evaluate vaccine performance.
Why This Matters
Understanding vaccine concepts beyond the basic “inject to prevent disease” level matters for anyone making decisions about vaccination programs. In post-collapse conditions, you may face decisions about which vaccines to use when supplies are limited, how to assess whether a vaccine is working, when to revaccinate, and how to explain vaccine effects and limitations to a skeptical community. These decisions require conceptual understanding, not just procedural knowledge.
As a community rebuilds biological knowledge, vaccine concepts also provide the foundation for eventually producing local vaccines from available biological materials. The history of vaccination shows that this is achievable with surprisingly simple tools — Jenner’s original cowpox observations led to one of the greatest medical achievements in history, conducted entirely without modern laboratory equipment.
Antigens: What the Immune System Recognizes
An antigen is any substance that the immune system can recognize and respond to. Vaccines work by presenting antigens to the immune system in a controlled, safe way, allowing it to build memory without causing disease.
Types of antigens used in vaccines:
Whole pathogens: the entire microorganism, either live-attenuated (weakened) or killed. Provides the full complement of antigens, producing broad immunity.
Protein subunits: just specific proteins from the pathogen surface. Safer (no risk from the whole organism) but may produce narrower immunity. Example: hepatitis B surface antigen.
Toxoids: inactivated bacterial toxins. The immune system learns to neutralize the toxin specifically. Example: tetanus toxoid is produced by treating tetanus toxin with formaldehyde.
Polysaccharide antigens: sugar-chain structures from bacterial capsules. Used for pneumococcus, meningococcus vaccines.
Post-collapse relevance: Whole-organism vaccines (killed or attenuated) are most producible with low technology. Subunit and polysaccharide vaccines require more sophisticated production. Understanding antigen types helps evaluate what is achievable with available resources.
Adjuvants: Amplifying the Response
An adjuvant is a substance added to vaccines to increase the immune response. Without adjuvants, many killed or subunit vaccines produce inadequate immunity.
How adjuvants work: Adjuvants activate innate immune cells at the injection site, creating local inflammation that amplifies the adaptive immune response. They essentially signal “danger here” to the immune system, ensuring it mounts a vigorous response to the antigen.
Common adjuvants:
- Aluminum salts (alum): the most widely used; suspends antigen and creates a depot that releases slowly
- Oil-in-water emulsions: used in influenza and some other vaccines
- Pattern recognition stimulants: mimic bacterial components to trigger innate immunity
Post-collapse consideration: If producing primitive vaccines from killed pathogens, aluminum-containing compounds (aluminum hydroxide, aluminum phosphate) can be produced from aluminum minerals and acids. Adding alum to a killed pathogen preparation can improve immune response significantly.
Natural adjuvants in traditional medicine: Various plant compounds stimulate immune activation. Saponins (from soapwort, quillaja bark, yucca) have demonstrated adjuvant activity. Traditional herbal preparations that include saponin-containing plants as carriers for other medicinal substances may achieve accidental adjuvant effect.
Vaccine Schedules: Why Timing Matters
Primary Series
Many vaccines require multiple doses to build full immunity. The first dose sensitizes the immune system; subsequent doses produce an amplified (anamnestic) response.
Two-dose example (tetanus):
- After first dose: low to moderate antibody levels after 2-4 weeks
- After second dose (4+ weeks later): dramatically higher antibody levels (10-100x greater), longer duration
Why spacing matters: doses given too close together (less than 3 weeks apart) do not allow time for the initial immune response to mature before the booster arrives. Doses given too far apart are not dangerous — just slightly less efficient. The minimum interval is more critical than the maximum.
Age-Based Schedules
The immune system matures with age. Some vaccines work better at certain ages:
- BCG (tuberculosis): given at birth or shortly after, when the immature immune system mounts the appropriate response type
- Live viral vaccines: most effective after maternal antibodies wane (6-12 months)
- Maternal antibody interference: infants are born with antibodies from their mother. These protect initially but also block vaccine response. This is why measles vaccine is given at 9-12 months — before this, maternal antibodies interfere.
Boosters
Immunity from vaccination wanes over time for most vaccines. Booster doses restore high levels.
Tetanus booster schedule:
- Primary series: 3 doses (0, 4-8 weeks, 6-12 months)
- Booster: every 10 years for life, or following a dirty wound if more than 5 years since last dose
Who needs boosters in post-collapse conditions: Adults who were vaccinated years ago may have waning immunity. During any vaccination campaign using existing stocks, prioritize:
- Children who have received no vaccines
- Adults with no documented vaccination history
- Adults with documented vaccination > 10 years ago for tetanus, > 5 years for other waning vaccines
Efficacy vs. Effectiveness
Vaccine efficacy: How well a vaccine works under ideal trial conditions. Measured as percentage reduction in disease in vaccinated vs. unvaccinated controlled groups.
Vaccine effectiveness: How well a vaccine works in real-world conditions — accounting for cold chain imperfections, population heterogeneity, emerging strains, etc. Always lower than efficacy.
Example: A tetanus vaccine with 95% efficacy may show 85% effectiveness in field conditions because some doses were temperature-compromised, some individuals had poor immune responses, and some were reinfected with tetanus despite vaccination.
Interpreting this:
- A 95% effective vaccine for smallpox means 5% of vaccinated individuals remain susceptible
- In a community of 500 with 80% vaccination coverage, approximately 20 vaccinated individuals plus 100 unvaccinated individuals remain susceptible
- This may or may not be enough to sustain an outbreak — depends on transmission dynamics
Primary vs. Secondary Vaccine Failure
Primary vaccine failure: the vaccine was given but the immune system did not respond. The individual is not protected.
Causes:
- Temperature-damaged vaccine
- Improper administration technique
- Individual immune deficiency (rare)
- Interference from maternal antibodies (children too young)
Secondary vaccine failure: the vaccine worked initially but immunity waned below protective levels before re-exposure occurred.
In practice without lab testing, distinguish by:
- Did vaccinated individuals develop disease when exposed? (Suggests failure)
- Was there a cluster of vaccinated individuals getting sick, suggesting cold chain failure? (Primary failure)
- Did older vaccinated individuals get sick while recent recipients did not? (Secondary failure — waning)
Understanding which type of failure is occurring guides the response: temperature check for primary failure, booster campaign for secondary failure.
Contraindications
When not to vaccinate:
Universal contraindications:
- Severe allergic reaction (anaphylaxis) to a previous dose of the same vaccine
- Severe illness at time of vaccination (defer until recovered — not because the vaccine is dangerous, but because immune response is diminished)
Live vaccine contraindications:
- Severe immunocompromise (HIV/AIDS, cancer treatment, severe malnutrition)
- Pregnancy (theoretical risk from live organisms — err on side of caution for most live vaccines)
- Recent passive antibody administration (blood transfusion, immune globulin) — interferes with response for several months
Mild illness is NOT a contraindication. A common cold, mild fever, or recent diarrhea does not prevent vaccination. This misconception causes significant under-vaccination when health workers defer mildly ill individuals who then do not return.
Communicating About Vaccines
In post-collapse communities, vaccine hesitancy can appear quickly — especially if adverse events occur or if institutional trust has been damaged by collapse events.
Key communication principles:
Be honest about what vaccines do and do not do. They reduce risk dramatically but not to zero. They can cause mild side effects. These are the same statements any honest vaccine advocate makes.
Explain the mechanism simply. “A small, weakened piece of the sickness is introduced so your body learns to fight it. Your body practices fighting something mild so it is ready when the real thing comes.”
Address adverse events openly. When a vaccine causes a sore arm, mild fever, or in rare cases a more serious reaction, acknowledge it honestly. Hiding adverse events destroys credibility.
Use demonstrated evidence. If 80% of a community is vaccinated and an epidemic passes without touching them while unvaccinated communities suffer, this visible evidence is powerful.
Involve trusted community figures. Vaccination is a social act as much as a medical one. Community leaders, traditional healers, and respected elders who model vaccination behavior do more for uptake than any lecture.